Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial #ACScancerchat (@drfrankiejs)

Professor Scolyer, what is the plan of attack? Are you going to hit it with Ipi+nivo? 10 years ago in June of 2013 I was diagnosed stage 4 melanoma brain and lung mets. Part of checkmate 067, Nivo arm of trial after SRS cyberknife for 3 small brain mets. Best Wishes!!! (@EdWilli63968626)

Important talk by @tompowles1 discussing emerging biomarkers for nivolumab + ipilimumab among patients with #mRCC in light of novel findings from the PRISM trial #KCRS23 #Biomarkers #KidneyCancer (@kidneycan)

Based on the latest updates from CLEAR and KN-426 ASCO-2023, it appears that IO-TKI may have lower durability compared to IO-IO. Should we consider IPI-NIVO as the first-line standard of care for patients with sarcomatoid features, irrespective of their IMDC risk! (@DrYukselUrun)

Phs II study of nivolumab with or without ipilimumab in refractory, metastatic squamous cell carcinoma of the anal canal #WCGIC2023 👉Trend for higher efficacy with dual ICI, but also more toxicity 👉We need predictive biomarkers @myESMO @OncoAlert @WCGIC (@ArndtVogel)

Excellent discussion @Juanmaoconnor!! "Genomic landscape of appendiceal adenocarcinoma" @michaelwhitewx and "Nivo with or without ipilimumab in m squamous cell carcinoma of the anal canal" @VanMorrisMD #WCGIC2023 (@CataniGreta)

Ipilimumab and nivolumab treatment in patients with stage III #UrothelialCancer. #ExpertCommentary @FaltasLab @WCMEnglanderIPM discusses work by van Dorp et al. in @NatureMedicine. #ReadNow > https://t.co/UIVqfb7oNw (@urotoday)

4-years OS update from HIMALAYA ph-3 trial in unresectable hepatocellular carcinoma. STRIDE regimen (Tremelimumab + Durvalumab) maintains significant long-term OS benefit vs sorafenib. At 4 years, 1/4 of the patients in the STRIDE arm remained alive. Very good results! #WCGIC2023 (@carlosbon78)

Very nice long term results of STRIDE arm in HIMALAYA trial. Single dose of Tremelimumab + Durva is really effective in uHCC. No difference in subgroup analysis 🤔. #WCGIC2023 (@BallenDF)

4-yr OS update from the phs 3 HIMALAYA trial of tremelimumab + durvalumab in HCC at #WCGIC2023 👉Excellent long-term survival data for STRIDE 👉4-yr OS rate of 19% (unprecedented in HCC) 👉Long-term OS observed in relevant subgroups, incl. pts with non-viral liver disease… https://t.co/ZTzq8PM6je (@ArndtVogel)

VESTIGE: Adjuvant immunotherapy in pts with resected GEA following preoperative chemotherapy with high risk for recurrence presented by @LizzySmyth1 at #WCGIC2023 🔎EORTC phs II study unfortunately⛔️ 👉Adj. Nivo/IPI did not improve DFS & OS compared to CTx @myESMO @WCGIC… https://t.co/lSFVIYRKdE (@ArndtVogel)

Adjuvant ipi/nivo in LA gastric cancer ypN1-N3 R0/R1 did not improved DFS… interesting, patients on postoperative FLOT arm continue to receive benefit of chemotherapy, VESTIGE results presented at #WCGIC2023 #GItumors #GIcancers (@MoniquMeneses)

The Phase 1B #NABUCCO trial: the use of either high or low-dose preoperative ipilimumab + nivolumab in patients with stage III #UrothelialCancer. Michiel Van Der Heijden, PhD @NKI_nl joins @CaPsurvivorship @DanaFarber in this discussion on UroToday > https://t.co/jkHcJteQM4 (@urotoday)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/L2XDmf5V2X (@OncLive)

Nivolumab + ipilimumab & chemotherapy continued to show durable benefit at 4 years compared w/ chemotherapy alone as first-line therapy in patients w/ advanced NSCLC, particularly in the PD-L1– and squamous populations. @DCarboneMD @OSUCCC_James #lcsm https://t.co/ShCsWZk0UO (@OncLive)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/y2zTzmIEVd (@OncLive)

🚨 Featured in Best of #JCO #ASCO23 edition: Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell #LungCancer in CheckMate 227 ➡️ https://t.co/kio9xc1V3G #LCSM #ImmunoOnc @JulieBrahmer (@JCO_ASCO)

Neoadjuvant nivolumab and ipilimumab for upper tract urothelial cancer #UTUC. @MTeoMD @MSKCancerCenter joins @UroCancerMD @VUMCurology to discuss encouraging data from this phase II #ClinicalTrial on UroToday > https://t.co/SOlu6wNq5H (@urotoday)

At #ASCO, Bradley McGregor (@BradMcG04) of @DanaFarber sat down to discuss his presentation regarding the results of the phase 2 study of #cabozantinib with #nivolumab and #ipilimumab in advanced renal cell #carcinoma (#RCC) with variant histologies https://t.co/WaSTSsZgQN (@OncData)

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Results From CheckMate 358 on Nivolumab With or Without Ipilimumab https://t.co/nKibMf3nBZ #skcsm #skincancer #oncology #ASCO23 @BhatiaS_MD @FredHutch (@ASCOPost)

Nivolumab + ipilimumab & chemotherapy continued to show durable benefit at 4 years compared w/ chemotherapy alone as first-line therapy in patients w/ advanced NSCLC, particularly in the PD-L1– and squamous populations. @DCarboneMD @OSUCCC_James #lcsm https://t.co/Kr3SDLUcTF (@OncLive)

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies. @BradMcG04 @DanaFarber #ASCO23 #kcsm https://t.co/aapAetsAiI (@OncLive)

📽️ Watch a video abstract at #JCO! @JulieBrahmer et al. have written an important article on cancer #immunotherapy with nivolumab plus ipilimumab vs. #chemotherapy in non-small-cell #LungCancer #LCSM 👉 https://t.co/EYOOHIHPWu (@JCO_ASCO)

Bobbie J. Rimel, MD, Isabelle L. Ray-Coquard, MD, PhD, on Cervical Squamous Carcinoma: Neoadjuvant Nivolumab Plus Ipilimumab https://t.co/WzAvAaSAV5 #gyncsm #cervicalcancer #oncdology #immunotherapy @BJRimelMD @ArcagyGineco (@ASCOPost)

Triplet therapy with cabozantinib, nivolumab, and ipilimumab demonstrated clinical meaningful activity in patients with renal cell carcinoma with variant histologies. @BradMcG04 @DanaFarber #ASCO23 #kcsm https://t.co/bOIEzFi4GB (@OncLive)

New #JITC article: Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study https://t.co/HGnmbOlaQa @OmidHamidMD @jmkirkwood @PAscierto (@jitcancer)

Non randomized study on nivo as well as ipi/nivo in IO naive pts with recurrent/metastatic Merkel cell carcinoma with similar ORR for both arms (60 and 58%) #RareCancers #RareDisease Presented by @BhatiaS_MD @UWMedicine #ASCO23 (@FunchainMD)

@tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23 (@apolo_andrea)

Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma @bvantine1 @ASCO #ASCO23 #scmsm https://t.co/jftf2zJQR5 (@OncLive)

Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit… https://t.co/5ziP6nUPzT (@ZiadBakouny)

@motzermd dives into the patient features, amount of treatment, and QOL of the phase 3 #CheckMate914 (part A) trial of Adjuvant Nivo/Ipi vs placebo for patients with localized high risk #RCC #renalcellcarcinoma after nephrectomy @ASCO #ASCO23 (@apolo_andrea)

Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert (@DrChoueiri)

#ASCO23: Today, Mon. 6/5 at 4:30 pm, @youngkwangchae of @LurieCancer, will present first results of ipilimumab and nivolumab in vulvar cancers of the @SWOG S1609 DART trial. https://t.co/mIxKrzHwvP #gyncsm (@LurieCancer)

Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC @DCarboneMD @OSUCCC_James @ASCO #ASCO23 #lcsm #oncology https://t.co/0ZmAus5Q0w (@OncLive)

Sub group analyses from CheckMate 914 (Part A): ⭕️Overall no OS benefit in ITT population. ⭕️Selected patients based on PDL1, sarcomatoid feature may get benefits from adjuvant NIVO-IPI buy study may not powered for those endpoints. @ASCO #ASCO23 @OncoAlert @montypal @AlbigesL… https://t.co/ECd092vvW1 (@DrYukselUrun)

#ASCO23 #lungcancer #lcsm @DCarboneMD First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4‑y clinical update & outcomes by tumor histologic subtype (THS). Abstract: LBA9023 | Pstr Bd #: 11 (@lcrf_org)

Updated OS with a 3-year follow-up of DICIPLE phase 3 trial (ipi+nivo 1rst-line #NSCLC): proof-of-concept of desescalation of #Immunotherapy is confirmed! #ASCO23 https://t.co/taAIf8fk7V Congrats to @actoffart1 and @gzalcman! Next step with DIAL trial: https://t.co/iaQIO0u9oV (@IFCTlung)

Phase II study of cabozantinib with nivolumab and ipilimumab in advanced #RenalCellCarcinoma with variant histologies. Presentation by @BradMcG04 @DanaFarber. #ASCO23 written coverage by @tchandra_uromd @UCDavisUrology on UroToday > https://t.co/KEeKCwpEUT @ASCO (@urotoday)

Triple Therapy in #nccRCC? ➡️Final results of #CaNI trial: triple therapy w/ cabo/nivo/ipi in pts with nccRCC -Safety concern: 74% G3-4 AE (10% cardiac) -CR: 0% -ORR all/1L: 18/21% -mPFS 8.9m -mOS NR, 12m OS 79% @BradMcG04 @OncoAlert @urotoday #ASCO23 ?doublet>triplet (@jordanciuro)

had a great time presenting our work on adaptively dosed ipi-nivo at #ASCO23 yesterday—lots of thoughtful engagement on potential strategies to reduce ICI toxicity in melanoma @MPostow (@jsmithymd)

Day 3 of #ASCO23 and we've had the chance to talk to @bvantine1 (@SitemanCenter) on SPEARHEAD-1 in synovial #sarcoma and cabozantinib with PD-1 & CTLA-4 inhibition in STS. Watch out for his interview and more on https://t.co/ys1d8pDAKO! @ASCO #SCMSM (@VJOncology)

.@bvantine1, of @SitemanCenter, highlighted insights on the use of cabozantinib w/ PD-1 & CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma LIVE at #ASCO23.. To get the latest updates from the @ASCO Annual Meeting, check back here: https://t.co/Jt115EnnnO (@OncLive)